Cellectar Biosciences, Inc.
CLRBW
CLRBW was delisted on the 20th of August, 2019.
4 hedge funds and large institutions have $35K invested in Cellectar Biosciences, Inc. in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
75% more capital invested
Capital invested by funds: $20K → $35K (+$15K)
33% more funds holding
Funds holding: 3 → 4 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
+$26.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIC
1
AWM Investment Company
New York
| $23K | +$26.2K | +106,600 | New |
|
|
CAM
2
Cormorant Asset Management
Boston,
Massachusetts
| $12K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| – | +$5 | +20 | +4% |
|
CLRBW Hedge Fund Activity: Q2 2017 in Review
4 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences, Inc. (CLRBW) for Q2 2017, worth a combined $35K — up 75% from $20K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new CLRBW positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was AWM Investment Company, opening a new position worth an estimated $26.2K.
- 4 institutional investors held Cellectar Biosciences, Inc. (CLRBW) as of Q2 2017, up from 3 in Q1 2017.
- Funds reported $35K of Cellectar Biosciences, Inc. stock for Q2 2017, up 75% quarter-over-quarter.
- 1 fund opened new Cellectar Biosciences, Inc. positions in Q2 2017 and 0 closed out, a net change of +1 holder.
- The largest Cellectar Biosciences, Inc. buyer in Q2 2017 was AWM Investment Company, an estimated $26.2K added.
Based on aggregated 13F filings for Q2 2017.